Related Experiment Videos
When antihypertensive monotherapy fails: fixed-dose combination therapy.
1Department of Medicine, University of Maryland School of Medicine, Baltimore, USA.
Southern Medical Journal
|July 6, 2000
Summary
Fixed-dose combination therapy using angiotensin-converting enzyme (ACE) inhibitor/calcium antagonist combinations offers superior blood pressure control for patients with hypertension. This approach improves treatment adherence and tolerability compared to escalating monotherapy doses.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Many patients do not achieve adequate blood pressure control with antihypertensive monotherapy.
- Hypertension management requires effective strategies beyond single-drug treatments.
Purpose of the Study:
- To review the efficacy and tolerance of fixed-dose angiotensin-converting enzyme (ACE) inhibitor/calcium antagonist combinations.
- To evaluate combination therapy as an alternative to escalating monotherapy for hypertension.
Main Methods:
- Systematic review of data on fixed-dose ACE inhibitor/calcium antagonist combinations.
- Analysis of efficacy, safety, and tolerability profiles of these combination therapies.
Main Results:
- Four fixed-dose ACE inhibitor/calcium antagonist combinations are available for hypertension treatment.
- These combinations provide superior blood pressure control without increasing adverse events compared to monotherapy.
- Combination therapy may mitigate class-specific side effects and benefit target organ damage, including renal dysfunction and left ventricular hypertrophy.
Conclusions:
- Fixed-dose combination therapy is a valuable option for patients whose hypertension is not controlled by initial monotherapy.
- This approach enhances patient compliance through improved tolerability and simplified administration.
- Combination therapy represents an effective strategy for managing resistant hypertension and protecting target organs.